Skip to main content
Shortcuts
Shortcuts
Registry Login
E-learning Login
Members Area Login
Search
Main navigation
Menu
EBMT
Who we are
What we do
EBMT Membership
50 Years of EBMT
Annual Report 2025
EBMT Partners
Media Partners
News
Society Opportunities
EBMT Registry
Registry News
Registry Release Updates
EuroTraCTOR
CAR-T Data Collection Initiative
Data Protection & Privacy
Informed Consent
Data Collection
Data Submission
Data Retrieval
Data Sharing
Data Quality
Registry Education & Training
Activity Survey
Benchmarking
Archived ProMISe and Castor Documents
Research
Publications
EBMT Publications list
My Paper of the Month
EBMT Studies
Current studies list
Open Survey/Study
Working Parties
Autoimmune Diseases Working Party (ADWP)
Acute Leukaemia Working Party (ALWP)
Chronic Malignancies Working Party (CMWP)
Cellular Therapy & Immunobiology Working Party (CTIWP)
Complications Working Party (CWP)
Haemoglobinopathies Working Party (HWP)
Inborn Errors Working Party (IEWP)
Infectious Diseases Working Party (IDWP)
Lymphoma Working Party (LWP)
Paediatric Diseases Working Party (PDWP)
Severe Aplastic Anaemia Working Party (SAAWP)
JACIE Working Party
Statistics
GoCART Coalition
Events
Annual Meeting 2027
Past Annual Meetings
Educational Events
Past Educational Events
EBMT Travel Grants
Related Events
Education
Educational Resources
Learning Projects
E-learning
EBMT & JACIE Books
EBMT Handbook
The EU CAR-T Handbook
The EBMT Textbook for Nurses
The JACIE Guide
JACIE Inspector Handbook
Clinical Cases
EBMT Exam
Physicians Preparatory Course
Nurses Preparatory Course
Basic & Translational Science
EBMT Travel Grants
Partnered Educational Projects
Nursing
Who we are
Working Party Nurses
Nursing Research Committee
Nursing Scientific Committee
Nursing Paediatric Committee
Nursing Global Education Committee
The Immune Effector Cell Forum
JACIE
About JACIE
JACIE Standards
Applicants
Inspectors
How to Become an Inspector
JACIE Inspector Handbook
Current Inspectors
Inspector Committee
JACIE Education
Top
Back to top
Meet the Inspector, Laura Lombardi
… allogeneic and autologous stem cells transplantations and
Car
-
T
cells therapies. Why did you decide to become a JACIE …
My paper of the Month - a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
… therapy with e.g. BTK inhibitors, cellular therapy with
CAR
-
T
cells and bispecific antibodies, are being rapidly …
Allogeneic Hematopoietic Cell Transplantation and CAR-T therapy for T-cell/histiocyte-rich Large B-cell Lymphoma (THRLBCL) A Retrospective Study of the EBMT Lymphoma Working Party
… Allogeneic Hematopoietic Cell Transplantation and
CAR
-
T
therapy for
T
-cell/histiocyte-rich Large B-cell Lymphoma (THRLBCL) A …
Report of the Autoimmune Diseases Working Party Educational Meeting – 22-23 September 2022 - London
… more advanced cellular therapies, such as regulatory
T
cells and
CAR
-
T
cell therapies, in patients affected by autoimmune … of hemophagocytic lymphohistiocytosis after HSCT and
CAR
-
T
cells therapy. Although it represents a rare adverse …
Posts from Zhemal Rakhmanova
… our microbiome influences on the response and toxicity of
CAR
-
T
therapy? And what also is important is that the last … the session but it’s just impossible to describe, so don’
t
miss the most interesting session for you next day! … a lot about the high importance of this event and I can’
t
wait to learn the newest investigations in heamatology and …
The Scientific Activity Reports
… including immunogenetics, conditioning regimens, and
CAR
T
cell therapy. Key studies focus on post-
CAR
T
fertility and its use in autoimmune diseases, in …
Message from the President
… at the next ASH meeting in 2022. With more than 3000
CAR
-
T
infusions registered in the EBMT Registry, EBMT and EHA are …
4th Nurses Research Study Day [Virtual]
… of life reported by children (2-18 ys) undergoing HSCT and
CAR
-
T
cell therapy. Parents were also included in the study. …
BMT Journal News
… articles and authors below: Manufacturing of primary
CAR
-NK cells in an automated system for the treatment of … Virus plasma DNA load: a novel prognostic biomarker in
CAR
-
T
therapy Pere Barba et al Trends in utilization of …
Accès national et besoins en thérapie CAR-T CD19 dans la région Euro
… Accès national et besoins en thérapie
CAR
-
T
CD19 dans la région Euro …
Pagination
Previous page
…
Page
18
Page
19
Page
20
Page
21
Current page
22
Page
23
Page
24
Page
25
Page
26
…
Next page